Glaukos (GKOS) reported $150.57 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 41.2%. EPS of -$0.18 for the same period compares to -$0.22 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $136.88 million, representing a surprise of +10%. The company delivered an EPS surprise of +39.6%, with the consensus EPS estimate being -$0.30.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues by product category- International- Glaucoma: $35.81 million versus $33.38 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +23.4% change. Revenues by product category- United States- Glaucoma: $93.5 million versus $84.57 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +58.1% change. Net Sales- Corneal Health: $21.3 million compared to the $18.83 million average estimate based on four analysts. The reported number represents a change of +15% year over year. Net Sales- Glaucoma: $129.3 million versus the four-analyst average estimate of $117.95 million. The reported number represents a year-over-year change of +46.7%.View all Key Company Metrics for Glaukos here>>>
Shares of Glaukos have returned +11.1% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Glaukos Corporation (GKOS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).